Skip to Main Content

Heads of Laboratories

Head shot of Sohail Tavazoie
Sohail Tavazoie, M.D., Ph.D.
Senior Attending Physician
Leon Hess Professor
Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology

Metastasis is responsible for the majority of cancer deaths. The Tavazoie laboratory employs a systems biology approach that integrates molecular, genetic, cellular, organismal, and clinical observations to discover and characterize key molecular regulators of metastasis, with the goal of developing new therapeutics for its prevention and treatment. This work is also uncovering basic insights into the mechanisms of gene regulation.

Metastatic disease is the primary cause of cancer mortality but remains poorly understood at the molecular level. The Tavazoie lab studies the molecular and cellular mechanisms underlying this process. Their work on metastasis has also uncovered previously unknown, fundamental mechanisms of gene regulation.

The lab employs unbiased genome-wide technologies to identify recurrent molecular alterations associated with enhanced metastatic capacity. Molecular and genetic studies in mice are used to implicate causal and critical genes that regulate this process, with clinical association studies confirming human relevance and biochemical studies implicating signaling pathways involved. This has led to the discovery that modulation of tissue-specific sets of small non-coding RNAs (microRNAs) drives metastasis formation in distinct cancer types by altering expression levels of critical downstream genes. These genes activate pathways that alter the cellular, metabolic, or matrix composition of the metastatic microenvironment; changes to the microenvironment may enhance the survival, immune-evasive, and invasive capacity of cancer cells. The lab’s findings have been applied toward the development of first-in-class metastasis-preventive therapeutics that target critical genes. Their long-term goal is to achieve broadly curative regimens in common cancers.

Furthermore, by studying how rare cancer cells are able to achieve extreme gene expression programs that enable metastasis formation, Tavazoie and his colleagues have gained basic insights into gene regulatory mechanisms. For example, modulation of specific transfer RNAs (tRNAs) has been shown to alter the expression levels of specific downstream target genes and to drive cancer progression. This has led to the discovery of specific tRNA-driven pathways. Moreover, mechanistic insights into gene regulation by an unusual class of small-RNAs, called tRNA-fragments, have also been uncovered. In addition to their relevance for metastatic disease, these basic studies are providing fundamental new insights into gene regulation mechanisms.


A.B. in molecular and cell biology, 1995
University of California, Berkeley

M.D., 2003
Harvard Medical School

Ph.D. in neuroscience, 2003
Harvard University


Internship in internal medicine, 2003–2004
Residency in internal medicine, 2004–2005
Brigham and Women’s Hospital/Harvard Medical School

Fellowship in oncology, 2005–2008
Sloan Kettering Institute


Harvard Medical School, 2004–2005

Sloan Kettering Institute, 2006–2008


Assistant Professor, 2009–2015
Associate Professor, 2015–2018
Professor, 2018–
The Rockefeller University

Senior Attending Physician, 2009–
The Rockefeller University Hospital


National Institutes of Health Director’s New Innovator Award, 2009

ASCO/AACR Young Investigator Award, 2009

Rita Allen Foundation Scholar, 2009

Emerald Foundation Young Investigator Award, 2009

Era of Hope Scholar, Department of Defense, 2010

The Rockefeller University Distinguished Teaching Award, 2013

Pershing Square Sohn Prize, 2015

Howard Hughes Medical Institute Faculty Scholar, 2016

Gabrielle H. Reem and Herbert J. Kayden Early-Career Innovation Award, 2017


Tavazoie, M.F. et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell 172, 825–840 (2018).

Goodarzi, H. et al. Modulated expression of specific tRNAs drives gene expression and cancer progression. Cell 165, 1416–1427 (2016).

Goodarzi, H. et al. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell 161, 790–802 (2015).

Alarcón, C.R. et al. N6-methyladenosine marks primary microRNAs for processing. Nature 519, 482–485 (2015).

Loo, J.M. et al. Extracellular metabolic energetics can promote cancer progression. Cell 160, 393–406 (2015).

Dr. Tavazoie is a faculty member in the David Rockefeller Graduate Program and the Tri-Institutional M.D.-Ph.D. Program.